Methods for delineating clinical risk groups in neuroblastoma by observing microrna signature and expression of dicer and drosha

本院覽號

公告日期

智財權狀態

28A-970530

know-how

摘要

技術優勢

Neuroblastoma (NB) is a common childhood tumor

\N

derived from primitive sympathetic neuroblasts and accounts for 15% of pediatric cancer deaths. Although current risk stratification is useful for selection of appropriate therapeutic regimens, there is still a lack of useful markers for predicting treatment failure in lower risk patients and high risk patients. The invention

應用範圍

\N

relates to progmostic markers specific for neuroblastoma that can predict tumor behavior and refine risk assessment in a patient diagnosed with neuroblastoma, and more particularly to methods for delineating neuroblastoma patients into clinical risk groups by observing MicroRNA signature and

expression of Dicer and Drosha.

創作人

Alice Yu, You-Chin Lin, Ruey-Jen Lin

